Verastem Inc (VSTM) - Net Assets

Latest as of March 2026: $81.78 Million USD

Based on the latest financial reports, Verastem Inc (VSTM) has net assets worth $81.78 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($227.81 Million) and total liabilities ($146.03 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore how efficiently does Verastem Inc generate cash to assess how effectively this company generates cash.

Key Net Assets Metrics

Metric	Value
Current Net Assets	$81.78 Million
% of Total Assets	35.9%
Annual Growth Rate	21.1%
5-Year Change	-34.68%
10-Year Change	-20.89%
Growth Volatility	439.94

Verastem Inc - Net Assets Trend (2010–2025)

This chart illustrates how Verastem Inc's net assets have evolved over time, based on quarterly financial data. Explore Verastem Inc (VSTM) long-term investment share to see how much of total assets are deployed in long-term investments.

Annual Net Assets for Verastem Inc (2010–2025)

The table below shows the annual net assets of Verastem Inc from 2010 to 2025. For live valuation and market cap data, see VSTM company net worth.

Year	Net Assets	Change
2025-12-31	$57.20 Million	+297.96%
2024-12-31	$-28.89 Million	-150.36%
2023-12-31	$57.37 Million	+21.07%
2022-12-31	$47.39 Million	-45.88%
2021-12-31	$87.56 Million	-24.04%
2020-12-31	$115.27 Million	+1506.83%
2019-12-31	$7.17 Million	-94.23%
2018-12-31	$124.30 Million	+115.48%
2017-12-31	$57.68 Million	-20.21%
2016-12-31	$72.30 Million	-29.45%
2015-12-31	$102.47 Million	+15.44%
2014-12-31	$88.77 Million	-24.42%
2013-12-31	$117.45 Million	+29.82%
2012-12-31	$90.47 Million	+808.65%
2011-12-31	$-12.77 Million	-494.50%
2010-12-31	$3.24 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Verastem Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 116499800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Common Stock	$8.00K	0.01%
Other Comprehensive Income	$5.23 Million	9.14%
Other Components	$1.22 Billion	2127.66%
Total Equity	$57.20 Million	100.00%

Verastem Inc Competitors by Market Cap

The table below lists competitors of Verastem Inc ranked by their market capitalization.

Company	Market Cap
TECSYS Inc. TO:TCS	$373.65 Million
Jacquet Metal Service SA PA:JCQ	$373.76 Million
GSI Technology Inc NASDAQ:GSIT	$373.80 Million
Robo.ai Inc. NASDAQ:AIIO	$374.02 Million
Real Brokerage Inc NASDAQ:REAX	$373.42 Million
SNDL Inc. NASDAQ:SNDL	$373.38 Million
Taiwan Steel Union Co Ltd TW:6581	$373.35 Million
Altimmune Inc NASDAQ:ALT	$373.19 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Verastem Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from -28,893,000 to 57,197,000, a change of 86,090,000.
Net loss of 209,471,000 reduced equity.
New share issuances of 196,976,000 increased equity.
Other comprehensive income increased equity by 5,229,000.
Other factors increased equity by 93,356,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	$-209.47 Million	-366.23%
Share Issuances	$196.98 Million	+344.38%
Other Comprehensive Income	$5.23 Million	+9.14%
Other Changes	$93.36 Million	+163.22%
Total Change	$-	%

Book Value vs Market Value Analysis

This analysis compares Verastem Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 5.15x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 0.12x to 5.15x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2010-12-31	$35.66	$4.25	x
2011-12-31	$-7.57	$4.25	x
2012-12-31	$57.85	$4.25	x
2013-12-31	$62.14	$4.25	x
2014-12-31	$41.28	$4.25	x
2015-12-31	$34.22	$4.25	x
2016-12-31	$23.46	$4.25	x
2017-12-31	$18.02	$4.25	x
2018-12-31	$21.52	$4.25	x
2019-12-31	$1.15	$4.25	x
2020-12-31	$9.02	$4.25	x
2021-12-31	$6.02	$4.25	x
2022-12-31	$2.94	$4.25	x
2023-12-31	$2.60	$4.25	x
2024-12-31	$-0.81	$4.25	x
2025-12-31	$0.83	$4.25	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Verastem Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -366.23%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -677.59%
• Asset Turnover: 0.13x
• Equity Multiplier: 4.31x
Recent ROE (-366.23%) is below the historical average (-208.23%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2010	-24.29%	0.00%	0.00x	1.11x	$-1.11 Million
2011	0.00%	0.00%	0.00x	0.00x	$-12.41 Million
2012	-35.35%	0.00%	0.00x	1.03x	$-41.03 Million
2013	-35.08%	0.00%	0.00x	1.07x	$-52.95 Million
2014	-60.12%	0.00%	0.00x	1.11x	$-62.24 Million
2015	-56.47%	0.00%	0.00x	1.10x	$-68.11 Million
2016	-50.40%	0.00%	0.00x	1.16x	$-43.67 Million
2017	-117.54%	0.00%	0.00x	1.56x	$-73.57 Million
2018	-58.27%	-271.11%	0.10x	2.23x	$-84.86 Million
2019	-2079.86%	-854.77%	0.12x	20.22x	$-149.93 Million
2020	-58.75%	-76.51%	0.57x	1.34x	$-79.25 Million
2021	-81.32%	-3468.10%	0.02x	1.24x	$-79.96 Million
2022	-155.75%	-2843.30%	0.03x	2.01x	$-78.55 Million
2023	-152.28%	0.00%	0.00x	2.61x	$-93.10 Million
2024	0.00%	-1306.37%	0.10x	0.00x	$-127.75 Million
2025	-366.23%	-677.59%	0.13x	4.31x	$-215.19 Million

Industry Comparison

This section compares Verastem Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $60,677,567
Average return on equity (ROE) among peers: -58.27%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Verastem Inc (VSTM)	$81.78 Million	-24.29%	1.79x	$373.46 Million
Aardvark Therapeutics, Inc. Common Stock (AARD)	$-34.80 Million	0.00%	0.00x	$86.88 Million
Abcellera Biologics Inc (ABCL)	$10.25 Million	-21.57%	1.29x	$1.60 Billion
Abeona Therapeutics Inc (ABEO)	$42.37 Million	-200.47%	0.88x	$323.66 Million
Acumen Pharmaceuticals Inc (ABOS)	$225.18 Million	-44.68%	0.02x	$183.46 Million
Abpro Holdings, Inc. (ABP)	$-22.46 Million	0.00%	0.00x	$2.00 Million
Absci Corp (ABSI)	$179.13 Million	-57.56%	0.19x	$804.47 Million
Arbutus Biopharma Corp (ABUS)	$203.00 Million	-189.21%	0.36x	$854.72 Million
ABVC Biopharma Inc (ABVC)	$60.67K	-43.96%	0.04x	$27.18 Million
Abivax SA American Depositary Shares (ABVX)	$56.72 Million	-25.23%	0.07x	$9.73 Billion
ACADIA Pharmaceuticals Inc (ACAD)	$-52.67 Million	0.00%	0.00x	$3.63 Billion

About Verastem Inc

NASDAQ:VSTM USA Biotechnology

Market Cap

$373.46 Million

Market Cap Rank

#14004 Global

#3257 in USA

Share Price

$4.25

Change (1 day)

-2.52%

52-Week Range

$4.13 - $10.77

All Time High

$119.64